AU2020380245A1 - Use of a Janus kinase inhibitor and a telomerase inhibitor for the treatment of myeloproliferative neoplasms - Google Patents
Use of a Janus kinase inhibitor and a telomerase inhibitor for the treatment of myeloproliferative neoplasms Download PDFInfo
- Publication number
- AU2020380245A1 AU2020380245A1 AU2020380245A AU2020380245A AU2020380245A1 AU 2020380245 A1 AU2020380245 A1 AU 2020380245A1 AU 2020380245 A AU2020380245 A AU 2020380245A AU 2020380245 A AU2020380245 A AU 2020380245A AU 2020380245 A1 AU2020380245 A1 AU 2020380245A1
- Authority
- AU
- Australia
- Prior art keywords
- days
- administered
- subject
- inhibitor
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962930251P | 2019-11-04 | 2019-11-04 | |
| US62/930,251 | 2019-11-04 | ||
| PCT/US2020/058718 WO2021091904A1 (en) | 2019-11-04 | 2020-11-03 | Use of a janus kinase inhibitor and a telomerase inhibitor for the treatment of myeloproliferative neoplasms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020380245A1 true AU2020380245A1 (en) | 2022-05-19 |
Family
ID=75848061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020380245A Pending AU2020380245A1 (en) | 2019-11-04 | 2020-11-03 | Use of a Janus kinase inhibitor and a telomerase inhibitor for the treatment of myeloproliferative neoplasms |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12391946B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4054594A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7767279B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220130669A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115666588A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020380245A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3156376A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL292596A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022005354A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202133854A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021091904A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024504367A (ja) * | 2021-01-22 | 2024-01-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | がんを治療及び改善するための方法 |
| EP4463151A4 (en) | 2022-01-19 | 2025-10-01 | Univ Northwestern | Agents Targeting Telomerase Reverse Transcriptase (TERT) to Treat Cancer and Sensitize Cancer Cells to Genotoxic Therapy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6162709B2 (ja) * | 2011-11-01 | 2017-07-12 | セルジーン コーポレイション | シチジンアナログの経口製剤を使用して癌を治療する方法 |
| KR102242077B1 (ko) * | 2012-11-15 | 2021-04-20 | 인사이트 홀딩스 코포레이션 | 룩솔리티니브의 서방성 제형 |
| PT3456333T (pt) | 2012-12-07 | 2020-06-01 | Geron Corp | Utilização do inibidor de telomerase imetelstate para o tratamento de síndrome mielodisplásica |
| US20150342982A1 (en) * | 2012-12-07 | 2015-12-03 | Geron Corporation | Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms |
-
2020
- 2020-11-03 JP JP2022525704A patent/JP7767279B2/ja active Active
- 2020-11-03 KR KR1020227018385A patent/KR20220130669A/ko active Pending
- 2020-11-03 WO PCT/US2020/058718 patent/WO2021091904A1/en not_active Ceased
- 2020-11-03 US US17/088,303 patent/US12391946B2/en active Active
- 2020-11-03 AU AU2020380245A patent/AU2020380245A1/en active Pending
- 2020-11-03 MX MX2022005354A patent/MX2022005354A/es unknown
- 2020-11-03 TW TW109138275A patent/TW202133854A/zh unknown
- 2020-11-03 EP EP20884376.3A patent/EP4054594A4/en active Pending
- 2020-11-03 CN CN202080091888.8A patent/CN115666588A/zh active Pending
- 2020-11-03 CA CA3156376A patent/CA3156376A1/en active Pending
-
2022
- 2022-04-28 IL IL292596A patent/IL292596A/en unknown
-
2025
- 2025-01-22 JP JP2025009336A patent/JP2025061603A/ja active Pending
- 2025-07-17 US US19/272,636 patent/US20260078379A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025061603A (ja) | 2025-04-10 |
| CN115666588A (zh) | 2023-01-31 |
| US12391946B2 (en) | 2025-08-19 |
| TW202133854A (zh) | 2021-09-16 |
| EP4054594A4 (en) | 2023-12-13 |
| JP2023500326A (ja) | 2023-01-05 |
| JP7767279B2 (ja) | 2025-11-11 |
| IL292596A (en) | 2022-07-01 |
| MX2022005354A (es) | 2022-10-21 |
| EP4054594A1 (en) | 2022-09-14 |
| CA3156376A1 (en) | 2021-05-14 |
| WO2021091904A1 (en) | 2021-05-14 |
| US20210269807A1 (en) | 2021-09-02 |
| US20260078379A1 (en) | 2026-03-19 |
| KR20220130669A (ko) | 2022-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260078379A1 (en) | Use of a Janus Kinase Inhibitor and a Telomerase Inhibitor for the Treatment of Myeloproliferative Neoplasms | |
| JP7288098B2 (ja) | 骨髄増殖性疾患および骨髄増殖性腫瘍を処置するためのテロメラーゼ阻害剤の使用 | |
| US12442000B2 (en) | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms | |
| RS64074B1 (sr) | Kombinacije imetelstata i venetoklaksa za lečenje akutne mijeloidne leukemije | |
| EP3512555A1 (en) | A hck inhibitor and a bcl-2 inhibitor for treating acute myeloid leukemia | |
| US20150342982A1 (en) | Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms | |
| HK40087531A (en) | Use of a janus kinase inhibitor and a telomerase inhibitor for the treatment of myeloproliferative neoplasms | |
| HK40018627A (en) | The telomerase inhibitor imetelstat for the treatment of myeloproliferative disorders and myeloproliferative neoplasms | |
| HK40018627B (en) | The telomerase inhibitor imetelstat for the treatment of myeloproliferative disorders and myeloproliferative neoplasms | |
| HK40009285B (en) | Use of the telomerase inhibitor imetelstat for the treatment of myelodysplastic syndrome | |
| HK40009285A (en) | Use of the telomerase inhibitor imetelstat for the treatment of myelodysplastic syndrome | |
| HK1212226B (en) | Use of the telomerase inhibitor imetelstat for the treatment of myelofibrosis | |
| OA17327A (en) | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms. | |
| EA041799B1 (ru) | Применение иметелстата для облегчения симптомов, являющихся следствием хронического миелогенного лейкоза или острого миелогенного лейкоза | |
| NZ748134B2 (en) | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |